Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron in Interferon-Refractory CML
NCT00037882Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2001
- Primary completion
- Dec 2003
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2001; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00037882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037882.